Boston Globe -- Henri Termeer has invested most of his professional life building Cambridge-based Genzyme into a global biotech powerhouse, and it could all come to an unceremonious end if French drug giant Sanofi-Aventis succeeds in its efforts to acquire the company. Yet people close to the Genzyme CEO tell Xconomy that Termeer has plenty of unfinished business and isn’t nearly ready to leave.
